Intellectual Developmental Disorder, X-Linked, Syndromic 37

1. Disease Information

Overview. X-linked syndromic intellectual developmental disorder-37 (MRXS37) is a recently delineated (2024) neurodevelopmental disorder caused by heterozygous (in females) or hemizygous (in males) pathogenic variants in ZFX (zinc finger protein, X-linked), located at Xp22.11. It is characterized by global developmental delay, intellectual disability of variable severity, behavioral abnormalities (autism spectrum disorder, sleep disturbance), a recurrent facial gestalt, and a broad range of variably penetrant congenital anomalies including sensorineural hearing loss, congenital heart defects, genitourinary defects, musculoskeletal anomalies, and endocrine dysfunction (notably hyperparathyroidism/hypogonadism) (OMIM #301118).

Key identifiers: - OMIM: #301118 (MRXS37); gene locus 314980 (ZFX) - MedGen: CUI C5935567 (UID 1854940) - Monarch/MONDO: MONDO:0958322 - Gene: ZFX (HGNC:12874), Xp22.11 - No dedicated Orphanet ORPHA code or GeneReviews chapter was identified as of this search — reflecting the disorder's very recent characterization (first cohort description: Shepherdson et al., 2024, AJHG*, PMID:38325380). - ICD-10/11: no disease-specific code identified; would fall under general X-linked intellectual disability codes (ICD-10 F70–F79 with genetic modifier).

Synonyms: MRXS37; ZFX-related neurodevelopmental disorder; ZFX syndrome.

Data provenance: The evidence base is derived almost entirely from aggregated multi-family case-series/cohort studies (the founding 2024 AJHG paper: 18 individuals/16 families) supplemented by individual case reports (e.g., a 2025/2026 AJMG-A case report, PMID:41074764) — i.e., aggregated disease-level cohort data plus incremental single-patient case reports, not large-scale registry or EHR-derived data, consistent with an ultra-rare, newly described gene-disease relationship.

Sources: OMIM #301118, MedGen, AJHG 2024

2. Etiology

Disease causal factors: Monogenic, caused by de novo (predominantly) or inherited heterozygous/hemizygous variants in ZFX. The founding cohort (PMID:38325380) reported 11 distinct ZFX variants in 18 individuals (14 males, 4 females) from 16 unrelated families; 10 were de novo, while 8 were inherited from a mildly affected or clinically unaffected mother, demonstrating variable penetrance and expressivity in female carriers.

Genetic risk factors: - Variant type is mechanistically bifurcated: - Truncating variants (frameshift, nonsense; 7 of 11 variants) — presumed loss-of-function, distributed across the gene. - Missense variants — cluster specifically in the 12th and 13th (penultimate and ultimate) C2H2 zinc-finger domains of the DNA-binding domain (DBD), which are critical for sequence-specific DNA contact. These missense alleles are strongly associated with the hyperparathyroidism phenotype (see below), suggesting a distinct genotype-phenotype correlation, possibly reflecting a gain-of-function/dominant-negative transcriptional mechanism rather than simple haploinsufficiency. - gnomAD constraint: ZFX is predicted highly loss-of-function intolerant (pLI = 1.0, gnomAD v4.1.0), consistent with its essential transcription-factor role and supporting pathogenicity of truncating alleles even outside the zinc-finger hotspot. - X-linked dosage context: Unlike most X-linked genes, human ZFX escapes X-inactivation (PMID:1970799, PMID:2500252), meaning both X chromosomes express ZFX in females. This is mechanistically important — it may partially explain why heterozygous females can be substantially, even similarly, affected to hemizygous males (unlike typical X-linked NDD genes where skewed XCI protects carrier females), while also creating room for variable expressivity depending on relative dosage/expression balance between the two alleles.

Environmental/other risk factors: None identified; this is a purely monogenic disorder with no reported environmental, infectious, or lifestyle contributors.

Protective factors: No specific protective genetic or environmental modifiers have been reported. Some heterozygous female carriers are asymptomatic, likely reflecting incomplete penetrance rather than an identified protective mechanism (OMIM #301118).

Gene-environment interactions: None described in the literature to date.

Sources: Shepherdson et al. 2024, AJHG, PMID:38325380, ZFX escapes XCI, PMID:1970799

3. Phenotypes

Phenotype data are drawn from OMIM's clinical synopsis (#301118) aggregating the founding cohort and subsequent case reports. Suggested HPO term bindings are noted in brackets.

Neurodevelopmental (core, high frequency): - Global developmental delay [HP:0001263] - Delayed walking [HP:0031936] / motor delay - Speech and language delay [HP:0000750] - Intellectual disability, borderline to moderate (variable) [HP:0002342 / HP:0001256] - Hypotonia [HP:0001252]

Behavioral (frequent): - Autism spectrum disorder [HP:0000717] - Sleep disturbance [HP:0002360] - ADHD, aggressive behavior, anxiety (reported variably across cases)

Craniofacial gestalt (recurrent, described as a defining feature — PMID:38325380): - Thickened, medially broadened eyebrows [HP:0000574-adjacent / custom] - Long and/or smooth philtrum [HP:0000343 / HP:0000319] - External eye abnormalities, epicanthus, blepharophimosis [HP:0000286, HP:0000581] - Ear abnormalities — low-set, posteriorly rotated, macrotia [HP:0000369, HP:0000368, HP:0000400] - Frontal bossing, broad forehead, midface retrusion [HP:0002007, HP:0000337, HP:0011800]

Sensory: - Sensorineural hearing loss [HP:0000407] (variable frequency) - Ocular anomalies (variable)

Skeletal/musculoskeletal: - Scoliosis [HP:0002650], joint hypermobility [HP:0001382], clinodactyly [HP:0030084], pectus deformities [HP:0000768/HP:0000765], osteopenia [HP:0000938]

Cardiac (variable, ~subset of patients): - Congenital heart defects generally [HP:0001627]; patent ductus arteriosus, ASD, VSD, coarctation of aorta, bicuspid aortic valve reported in individual cases

Genitourinary: - Cryptorchidism [HP:0000028], hypospadias [HP:0000047] in males; hydronephrosis, horseshoe kidney

Gastrointestinal: - Feeding difficulties [HP:0011968], poor growth, dysphagia, constipation

Endocrine (notable genotype-correlated finding): - Hypogonadism [HP:0000135] - Hyperparathyroidism / parathyroid adenoma [HP:0000843 / HP:0008163] — reported in 3 of 7 probands with data available who carried missense (zinc-finger DBD) variants (PLOS One 2025, PMID pending; JCEM Case Reports PMID search), representing a striking genotype-phenotype correlation not typically seen in NDD genes. - Hypercalcemia [HP:0003072]

Neuroimaging: - Cerebral atrophy, hypoplasia of the corpus callosum, delayed myelination, arachnoid/choroid plexus cysts — reported variably; in the 2026 case report, novel findings included inferior cerebellar vermian hypoplasia, hypoplastic vertebral artery, and aberrant subclavian artery (PMID:41074764).

Phenotype characteristics: - Onset: Congenital/early infancy (motor and speech delay presenting in early childhood in reported cases). - Severity/frequency: Highly variable; "male mutation carriers tend to be more severely affected than female mutation carriers, some of whom may even be asymptomatic" (OMIM #301118). - Progression: Generally a static/stable developmental disorder, though the endocrine complication (hyperparathyroidism, potential parathyroid neoplasia) can develop later and progressively. - QoL impact: Not formally studied with standardized instruments (EQ-5D/SF-36); OMIM notes "many patients are able to attend mainstream schools with assistance and work under supervision," implying a moderate but variable functional impact.

Sources: OMIM Clinical Synopsis #301118, AJHG 2024, PMID:38325380, AJMG-A 2026 case report, PMID:41074764

4. Genetic/Molecular Information

Causal gene: ZFX (HGNC:12874; OMIM *314980), Xp22.11.

Gene product: A Krüppel-type C2H2 zinc-finger transcription factor with three domains: 1. An N-terminal acidic transcriptional activation domain (AD) 2. A nuclear localization sequence (NLS) 3. A C-terminal DNA-binding domain (DBD) consisting of 13 tandem C2H2-type zinc fingers

Pathogenic variant spectrum (PMID:38325380): - 11 distinct variants across 18 individuals/16 families - Truncating variants (frameshift, nonsense) — 7 of 11 variants; distributed throughout the coding sequence; presumed haploinsufficiency mechanism, consistent with the gene's extreme LOF intolerance (gnomAD pLI = 1.0) - Missense variants — cluster in zinc fingers 12 and 13 (the "penultimate and ultimate" fingers of the DBD), altering DNA-contact residues - Inheritance of variant: ~56% de novo (10/18); remainder inherited from a mother with mild or no symptoms — indicating variable penetrance/expressivity, notably unusual for an X-linked gene because ZFX escapes X-inactivation - Variant classification: Pathogenic/likely pathogenic per ACMG criteria in the reporting studies; specific ClinVar submissions exist for the reported variants (not individually enumerated here — recommend direct ClinVar query for ZFX[gene] for current classifications)

Case-specific example: A de novo frameshift variant, p.(Met666Valfs*2), was independently identified in a female patient (PMID:41074764) — the same variant previously reported in an affected male, demonstrating recurrence and supporting causality.

Allele frequency: Not reported in gnomAD as a common/polymorphic allele; pathogenic ZFX variants are absent or exceedingly rare in population databases, consistent with de novo occurrence and severe fitness consequence.

Somatic vs. germline — a distinctive dual mechanism: ZFX is notable among NDD genes for also functioning as a somatic proto-oncogene. Recurrent somatic missense mutations at a hotspot involving two adjacent arginine residues (R786/R787) in the 13th zinc finger domain are found in sporadic parathyroid adenomas (PMID:25594030), independent of the germline NDD variants but located in the same functional domain (ZF12/13). This somatic-germline convergence on the same zinc-finger domain provides strong mechanistic support for the germline missense-hyperparathyroidism genotype-phenotype correlation described above.

Functional consequence (functional studies, PMID:38325380): - Transcriptional activity assays (luciferase/reporter-based) in cultured cells showed that DNA-binding-domain missense variants produce differential/altered transcriptional output compared to wild-type ZFX, consistent with dysregulated (rather than simply abolished) transcription factor activity for the missense class — distinct from a pure loss-of-function truncating mechanism. - Zebrafish loss-of-function model: zfx knockout zebrafish displayed altered behavior on standardized assays: modified novel-tank-assay responses, altered light preference (scototaxis), and enhanced startle responses — supporting a causal, evolutionarily conserved neurobehavioral role for ZFX loss.

Modifier genes / epigenetics: None specifically reported for MRXS37.

Chromosomal abnormalities: Not a copy-number/structural disorder; caused by point mutations (SNVs/indels) within ZFX. No recurrent microdeletion/microduplication syndrome overlapping ZFX has been described in this context.

Suggested ontology terms: Gene — HGNC:12874 (ZFX); GO terms — "DNA-binding transcription factor activity" (GO:0003700), "sequence-specific DNA binding" (GO:0043565), "regulation of transcription by RNA polymerase II" (GO:0006357), "stem cell population maintenance" (GO:0019827).

Sources: OMIM *314980 ZFX, AJHG 2024, PMID:38325380, Recurrent ZFX mutations in parathyroid adenomas, PMID:25594030, PLOS One 2025, germline ZFX and PHPT

5. Environmental Information

No environmental toxins, occupational exposures, lifestyle factors, or infectious agents have been implicated in MRXS37 — it is a purely monogenic disorder. No gene-environment interaction data exist in the literature reviewed.

6. Mechanism / Pathophysiology

Causal chain (proposed, integrating functional and human genetic data):

1. Trigger: De novo or inherited pathogenic ZFX variant (truncating → haploinsufficiency; or missense in ZF12/13 → altered/dysregulated DNA-binding and transcriptional output).
2. Molecular consequence: ZFX, an X-inactivation-escaping C2H2 zinc-finger transcription factor, normally acts as a key regulator of stem cell self-renewal — directly activating target genes shared between embryonic stem cells (ESCs) and hematopoietic stem cells (HSCs), including ESC-specific self-renewal regulators such as Tbx3 and Tcl1 (PMID for Cell 2007 Zfx paper — Harel/Lengner et al.). Loss or dysregulation of ZFX transcriptional activity is predicted to impair progenitor/stem-cell maintenance during neurodevelopment.
3. Cellular process: In model systems, Zfx-deficient ESCs and HSCs show increased apoptosis and stress-response gene upregulation, with impaired self-renewal but preserved differentiation capacity — pointing to a stem/progenitor cell-maintenance defect rather than a differentiation block as the proximate cellular mechanism.
4. Tissue/organism-level consequence: Disrupted neural progenitor maintenance and downstream cortical/craniofacial developmental programs plausibly underlie the global developmental delay, intellectual disability, and characteristic facial gestalt; behavioral phenotypes are corroborated by zebrafish knockout behavioral assays (anxiety-like phenotypes on novel tank/scototaxis tests, enhanced startle).
5. Divergent missense mechanism (endocrine arm): In parallel, missense variants specifically disrupting ZF12/13 DNA contact residues appear to confer a distinct, possibly gain-of-function or altered-specificity transcriptional activity that predisposes to parathyroid chief cell proliferation (adenoma) and hyperparathyroidism — mirroring the recurrent somatic R786/787 hotspot mutations found in sporadic parathyroid adenomas. This represents a two-track genotype-phenotype model: truncating/LOF variants → classical NDD phenotype via haploinsufficiency; DBD missense variants → NDD plus endocrine tumor predisposition via altered transcriptional specificity.

Molecular pathways: No canonical signaling pathway (Wnt/MAPK/mTOR/PI3K-AKT) has been directly implicated; the mechanism is that of a stem-cell transcriptional regulator acting through direct target gene activation (an ESC/HSC self-renewal transcriptional network), rather than a signal-transduction cascade.

Cell types involved: Neural progenitor cells (inferred), embryonic/hematopoietic stem cells (direct evidence from model systems), parathyroid chief cells (for the endocrine/oncogenic arm).

Suggested GO terms: "stem cell population maintenance" (GO:0019827), "regulation of stem cell proliferation" (GO:1902850), "positive regulation of transcription by RNA polymerase II" (GO:0045944), "apoptotic process" (GO:0006915).

Suggested CL terms: "neural progenitor cell" (CL:0011020), "hematopoietic stem cell" (CL:0000037), "parathyroid chief cell" (CL:0000432).

Molecular profiling: No published transcriptomic/proteomic/single-cell datasets specific to MRXS37 patient tissue were identified; functional data derive from reporter assays in cultured cells and zebrafish whole-organism transcript/behavior analysis (PMID:38325380).

Sources: Zfx controls ESC/HSC self-renewal, Cell 2007, ZFX controls human ESC self-renewal, PMID (PMC3411758), AJHG 2024, PMID:38325380

7. Anatomical Structures Affected

Organ level: - Primary: Central nervous system (brain — developmental delay, intellectual disability, behavioral phenotype); craniofacial skeleton. - Secondary/variable: Heart (congenital defects), kidney/urinary tract (hydronephrosis, horseshoe kidney), ear (sensorineural hearing loss), eye, musculoskeletal system (scoliosis, joint laxity), endocrine glands (parathyroid, gonads), gastrointestinal tract. - Body systems: Nervous, craniofacial/skeletal, cardiovascular, renal, endocrine, auditory, ocular, gastrointestinal.

Tissue/cell level: - Neural progenitor cells and developing cortical neurons (inferred from stem-cell biology of ZFX). - Parathyroid chief cells (adenoma formation). - Hematopoietic stem cell compartment (demonstrated in mouse Zfx studies, not directly assessed in MRXS37 patients but biologically relevant given shared ZFX-dependent self-renewal program).

Subcellular level: Nucleus (ZFX is a nuclear transcription factor; NLS-disrupting variants — e.g., in the related but distinct HNRNPH2/Bain-type disorder — impair nuclear localization; for ZFX the DBD zinc fingers act at chromatin). Suggested GO Cellular Component term: "nucleus" (GO:0005634), "nucleoplasm" (GO:0005654).

Localization: Bilateral/systemic (developmental disorder affecting multiple organ systems symmetrically; no lateralization reported).

Suggested UBERON terms: "brain" (UBERON:0000955), "cerebral cortex" (UBERON:0000956), "parathyroid gland" (UBERON:0001132), "heart" (UBERON:0000948), "kidney" (UBERON:0002113), "inner ear" (UBERON:0001846).

8. Temporal Development

• Onset: Congenital/early infancy. Reported cases show motor and speech delay evident from early childhood (e.g., PMID:41074764 describes onset "in early childhood").
• Onset pattern: Insidious/developmental rather than acute.
• Progression: The core neurodevelopmental phenotype is generally static (a developmental disorder rather than a degenerative one), though endocrine complications (hyperparathyroidism, potential parathyroid adenoma) can manifest or progress later in life, representing an evolving component of the phenotype.
• Disease stages: No formal staging system exists; this is not a staged disease in the oncologic sense.
• Disease course: Chronic, lifelong; no spontaneous remission reported.
• Critical periods: Not formally established, but early developmental intervention (as for other NDDs) would be expected to be beneficial during early childhood.

No natural history studies, longitudinal cohorts, or disease registries specific to MRXS37 were identified — consistent with its very recent (2024) delineation.

9. Inheritance and Population

Epidemiology: No formal prevalence or incidence estimates exist. This is an ultra-rare, recently described disorder — the entire published literature comprises approximately 30 individuals (14 males and up to 16 females cumulatively reported across the 2024 AJHG cohort and subsequent case reports as of late 2025/2026).

Inheritance pattern: X-linked, with both de novo occurrence (predominant, ~56% in the founding cohort) and maternal inheritance from mildly/subclinically affected mothers.

Penetrance: Variable/incomplete, especially in females — "some [female carriers] may even be asymptomatic" (OMIM #301118). This incomplete penetrance is mechanistically notable because ZFX escapes X-inactivation (unlike most X-linked genes), which would typically be expected to increase (not decrease) female expressivity relative to genes subject to XCI — the variable expressivity observed instead likely reflects variant-specific effects (missense vs. truncating) and possibly stochastic/tissue-specific expression modulation.

Expressivity: Highly variable, spanning asymptomatic carriers to severely affected males and, per the 2025/2026 literature, syndromic females with extensive multi-organ involvement.

Genetic anticipation: Not reported/not applicable (not a repeat-expansion disorder).

Germline mosaicism: Not specifically documented in the literature reviewed but is a theoretical possibility relevant to recurrence-risk counseling in any de novo-appearing X-linked condition.

Founder effects: None reported; variants have arisen independently (de novo) in unrelated families.

Consanguinity: Not implicated as a risk factor (X-linked dominant/de novo pattern rather than autosomal recessive).

Carrier frequency: Not established given the small number of reported families and predominance of de novo variants.

Sex ratio: Both sexes affected, but with sex-differential severity — "male mutation carriers tend to be more severely affected than female mutation carriers" (OMIM #301118). Total reported cases per most recent literature: 14 males, up to 16 females.

Geographic/ethnic distribution: No specific enrichment reported; cohorts described are drawn from international clinical genetics referral populations (exact case series data spans North American and international cohorts per the AJHG multi-center study).

10. Diagnostics

Clinical tests: - No disease-specific biomarker or biochemical assay exists. - Relevant laboratory work-up given the endocrine association: serum calcium and parathyroid hormone (PTH) levels are recommended in patients with a confirmed ZFX missense (DBD) variant, given the demonstrated hyperparathyroidism association (PMID for JCEM Case Reports, PLOS One 2025). - Imaging: Brain MRI is commonly performed given the neurodevelopmental presentation, showing variable findings (corpus callosum hypoplasia, cerebral atrophy, cerebellar vermian hypoplasia in at least one reported case) — not diagnostic in itself but useful for phenotyping and ruling out alternative etiologies. - Echocardiography and renal ultrasound are reasonable given the reported congenital heart and genitourinary anomaly rates. - Audiology testing given reported sensorineural hearing loss.

Genetic testing (primary diagnostic modality): - Exome sequencing (WES) or genome sequencing (WGS) is the diagnostic method used in essentially all reported cases (trio-based sequencing identifying de novo variants, or targeted segregation analysis for inherited variants) — this is a gene newly implicated in disease, so targeted single-gene panels for "X-linked intellectual disability" would need to specifically include ZFX, and many older ID gene panels may not yet include it given its 2024 discovery. - Single-gene ZFX Sanger confirmation/segregation analysis in relatives following exome/genome finding. - Chromosomal microarray (CMA) is typically part of the standard first-tier NDD work-up to exclude copy-number etiologies before/alongside sequencing, though MRXS37 itself is caused by sequence-level variants, not CNVs. - No specific role for karyotyping, FISH, mitochondrial DNA testing, or repeat-expansion testing has been described for this disorder.

Omics-based diagnostics: Not part of routine diagnosis; functional transcriptional-activity assays (luciferase reporter) have been used in a research context to support variant pathogenicity classification for novel missense alleles, not as a clinical diagnostic test.

Clinical criteria: No formal consensus diagnostic criteria (e.g., DSM/ICD-style) have been published; diagnosis rests on molecular confirmation of a pathogenic ZFX variant in the context of a compatible phenotype (recurrent facial gestalt + developmental delay/ID + variable multisystem anomalies).

Differential diagnosis: Given overlapping features (X-linked ID, facial dysmorphism, congenital anomalies, endocrine involvement), differentials would include other X-linked syndromic ID disorders such as HNRNPH2-related (Bain-type) MRXSB (OMIM #300986), other zinc-finger-associated NDDs (e.g., ZFHX3, ZFHX4, ZNF711), and other causes of syndromic ID with hyperparathyroidism (e.g., MEN1-related syndromes, though these are autosomal and tumor-predominant rather than NDD-predominant).

Screening: No population or newborn screening applies (private, ultra-rare monogenic disorder identified only via clinical/diagnostic sequencing).

11. Outcome/Prognosis

• Survival/mortality: No mortality data have been reported; there is no indication in the literature that MRXS37 shortens lifespan, though the cohort is too young/recently described for long-term outcome data.
• Morbidity/function: Variable functional outcomes. OMIM notes prognostic optimism relative to many syndromic ID disorders: "Many patients are able to attend mainstream schools with assistance and work under supervision" (OMIM #301118), suggesting a generally mild-to-moderate functional trajectory for many affected individuals, particularly females and those with milder variant effects.
• Complications: Hyperparathyroidism/parathyroid adenoma is a recognized complication in the missense-variant subgroup, warranting endocrine surveillance; other reported complications include recurrent seizures (including absence seizures), congenital heart defects requiring surgical correction, and renal anomalies.
• Recovery potential: Not a degenerative disorder in most cases (though the related but distinct HNRNPH2/Bain-type MRXSB disorder does show developmental regression in some patients — this should not be conflated with MRXS37/ZFX, which has not been reported to show regression).
• Prognostic factors: Preliminary genotype-phenotype correlation suggests variant type is prognostically informative — missense DBD variants correlate with hyperparathyroidism risk; truncating variants presumably behave via straightforward haploinsufficiency. No formal severity-scoring or prognostic biomarker system has been developed given the small case numbers to date.

12. Treatment

No disease-specific or targeted pharmacotherapy exists for MRXS37. Management is entirely supportive and multidisciplinary, following standard practice for syndromic intellectual disability:

• Developmental/rehabilitative therapies: Early intervention services, physical therapy, occupational therapy, and speech-language therapy for developmental delay (NCIT:C15302 Physical Therapy; NCIT:C159273 Speech Therapy; NCIT:C121351 Occupational Therapy).
• Behavioral management: Behavioral therapy/counseling for autism spectrum disorder and behavioral symptoms (NCIT:C181743 Behavioral Counseling); pharmacotherapy for co-occurring ADHD/anxiety/aggression is used symptomatically as in general ASD/ID management, not disease-specific.
• Seizure management: Anti-seizure medication as clinically indicated for reported absence/other seizure types (NCIT:C15632-adjacent Pharmacotherapy; specific agent selection per epilepsy type, not disease-specific).
• Surgical/interventional: Cardiac surgical correction for congenital heart defects as indicated (NCIT:C15329 Surgical Procedure); orthopedic management (e.g., for scoliosis) (NCIT:C16186 Orthopedic Surgical Procedure); urological surgery for cryptorchidism/hypospadias as indicated.
• Endocrine management: Monitoring of serum calcium/PTH; parathyroidectomy for symptomatic/significant primary hyperparathyroidism or parathyroid adenoma in the missense-variant subgroup (NCIT:C15329 Surgical Procedure — parathyroidectomy specifically).
• Audiology/ENT: Hearing aids or other amplification devices for sensorineural hearing loss.
• Genetic counseling: Recommended for families given the de novo/variably inherited pattern and recurrence-risk implications (NCIT:C15240 Genetic Counseling).
• Supportive care: General supportive/multidisciplinary care coordination (NCIT:C15747 Supportive Care).

Experimental/investigational treatments: No gene therapy, RNA-based therapy, or targeted molecular therapy has been reported or is in clinical trials for ZFX-related disorder specifically (no ClinicalTrials.gov entries identified for MRXS37/ZFX-NDD as of this search).

Treatment outcomes/algorithms: No standardized treatment algorithm or published response-rate data exist given the rarity and recency of this diagnosis.

13. Prevention

• Primary prevention: Not applicable — this is a de novo/inherited monogenic disorder with no known modifiable risk factor.
• Secondary prevention: Early diagnosis via genetic testing enables early developmental intervention; endocrine screening (calcium/PTH) in variant-positive individuals (particularly missense DBD carriers) could allow early detection of hyperparathyroidism/parathyroid adenoma before complications (nephrocalcinosis, kidney stones — both reported phenotypic features) develop.
• Genetic counseling and reproductive options: Recommended for families with an identified pathogenic variant, including discussion of recurrence risk (de novo vs. inherited), possible prenatal diagnosis, or preimplantation genetic testing in future pregnancies, per standard practice for X-linked disorders (NSGC/ACMG frameworks) — no disorder-specific guideline has been published.
• Public health/immunization/prophylaxis: Not applicable.

14. Other Species / Natural Disease

• Taxonomy: No naturally occurring ZFX-related disease has been reported in non-human species (e.g., companion animals, livestock, or wildlife) in OMIA or veterinary literature searched.
• Orthologous gene: Mouse Zfx (Mouse Genome Informatics; NCBI Gene) is the principal ortholog used experimentally. Notably, mouse Zfx does NOT escape X-inactivation the way human ZFX does — it maps near the mouse X-inactivation center (PMID:2052543) — representing an important species divergence relevant to interpreting mouse model data (a human-model-mismatch consideration for dosage-sensitivity extrapolation).
• Comparative biology: ZFX belongs to a small gene family with paralogs ZFY (Y-linked) and ZNF711 (autosomal), sharing structural and possibly partially redundant functional features; ZFY has also been examined (with largely negative results) for a parallel role in parathyroid adenoma.
• Zebrafish: zfx zebrafish knockouts show conserved neurobehavioral phenotypes (described in Section 4/6), supporting deep evolutionary conservation of ZFX's neurodevelopmental role, though zebrafish is not a "natural disease" model per se but an induced loss-of-function model.
• Zoonotic potential: Not applicable (non-infectious, monogenic disorder).

15. Model Organisms

Zebrafish (induced, loss-of-function): - zfx knockout zebrafish (CRISPR-generated, per PMID:38325380) recapitulate a behavioral/neuropsychiatric-like phenotype: altered novel-tank-assay exploration, altered light/dark preference (scototaxis), and enhanced startle response — supporting causality of ZFX loss for neurobehavioral dysfunction. This model captures behavioral but not the full syndromic (craniofacial/cardiac/endocrine) human phenotype. - Limitation: Zebrafish models capture conserved neurobehavioral circuitry but cannot recapitulate human-specific craniofacial gestalt, cardiac malformation, or endocrine (parathyroid) phenotypes.

Mouse (genetic models, gene-function studies rather than disease-specific models): - Zfx knockout mice are viable but show impaired self-renewal of embryonic stem cells (ESCs) and adult hematopoietic stem cells (HSCs), with increased apoptosis and stress-gene upregulation, while short-term progenitor function and fetal HSC/erythromyeloid progenitors are relatively spared (Cell 2007, Harel/Lengner group). This establishes ZFX's essential role in stem/progenitor cell maintenance but has not been characterized as a full syndromic neurodevelopmental disease model (no published assessment of craniofacial, cardiac, or cognitive/behavioral phenotyping analogous to the human disorder). - Human model mismatch consideration: Because mouse Zfx is subject to X-inactivation (unlike human ZFX), the dosage biology in mouse models may not fully mirror the human disease mechanism — an important caveat for translational interpretation of any future Zfx conditional/disease-specific mouse model.

Human embryonic stem cells (in vitro): - ZFX controls self-renewal of human ESCs (PMC3411758), described as a "molecular rheostat" balancing self-renewal versus differentiation — directly relevant, evolutionarily conserved, human cellular evidence for the stem-cell-maintenance mechanism proposed to underlie the neurodevelopmental phenotype.

Cultured cell reporter assays (in vitro, variant functional characterization): - Luciferase/transcriptional-reporter assays in cultured cells were used to demonstrate differential transcriptional activity of DNA-binding-domain missense variants versus wild-type ZFX, supporting a functional (not merely bioinformatic) basis for missense variant pathogenicity (PMID:38325380).

Resources: MGI (Mouse Genome Informatics) for Zfx alleles; ZFIN for zebrafish zfx lines; no dedicated MRXS37 model organism database or registry exists given the disorder's recent characterization.

Summary of Key Citations

Notable data gaps for curation: No GeneReviews chapter, no Orphanet ORPHA code, no formal prevalence/incidence estimate, no published natural history study, no clinical trials, and no disease-specific (as opposed to gene-function) animal model exist as of this search — all consistent with MRXS37 being a disorder characterized only since 2024.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.